BR112014030285A2 - composição farmacêutica para tratar um distúrbio ou doença inflamatória da pele - Google Patents

composição farmacêutica para tratar um distúrbio ou doença inflamatória da pele

Info

Publication number
BR112014030285A2
BR112014030285A2 BR112014030285A BR112014030285A BR112014030285A2 BR 112014030285 A2 BR112014030285 A2 BR 112014030285A2 BR 112014030285 A BR112014030285 A BR 112014030285A BR 112014030285 A BR112014030285 A BR 112014030285A BR 112014030285 A2 BR112014030285 A2 BR 112014030285A2
Authority
BR
Brazil
Prior art keywords
disease
inflammatory skin
skin disorder
treating
pharmaceutical composition
Prior art date
Application number
BR112014030285A
Other languages
English (en)
Other versions
BR112014030285B1 (pt
BR112014030285A8 (pt
Inventor
P St Laurent Joseph
Original Assignee
Olatec Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Ind Llc filed Critical Olatec Ind Llc
Publication of BR112014030285A2 publication Critical patent/BR112014030285A2/pt
Publication of BR112014030285A8 publication Critical patent/BR112014030285A8/pt
Publication of BR112014030285B1 publication Critical patent/BR112014030285B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo farmacãšutica para tratar um distãšrbio ou doenã‡a inflamatã“ria da pele” a presente invenã§ã£o ã© dirigida a um mã©todo para tratar doenã§as inflamatã³rias da pele tais como dermatite, psorã­ase, e acne, e rosã¡cea, pela administraã§ã£o de 3-metanosulfonilpropionitrila ou um sal ou solvato farmaceuticamente aceitã¡vel da mesma para um indivã­duo em necessidade do mesmo. o mã©todo alivia os sintomas da doenã§a tratada. o composto ativo pode ser administrado por uma via sistãªmica ou via tã³pica. administraã§ã£o tã³pica ã© a via preferida de administraã§ã£o.
BR112014030285-5A 2012-06-05 2013-06-03 Uso de 3-metanosulfonilpropionitrila BR112014030285B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655936P 2012-06-05 2012-06-05
US61/655936 2012-06-05
PCT/US2013/043921 WO2013184586A1 (en) 2012-06-05 2013-06-03 Method for treating skin inflammatory diseases

Publications (3)

Publication Number Publication Date
BR112014030285A2 true BR112014030285A2 (pt) 2017-06-27
BR112014030285A8 BR112014030285A8 (pt) 2021-06-22
BR112014030285B1 BR112014030285B1 (pt) 2022-03-29

Family

ID=49712530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030285-5A BR112014030285B1 (pt) 2012-06-05 2013-06-03 Uso de 3-metanosulfonilpropionitrila

Country Status (10)

Country Link
US (3) US9078869B2 (pt)
EP (1) EP2854784B1 (pt)
JP (1) JP6185575B2 (pt)
KR (1) KR102112883B1 (pt)
CN (1) CN104411303B (pt)
AU (1) AU2013271836B2 (pt)
BR (1) BR112014030285B1 (pt)
CA (1) CA2875052C (pt)
MX (1) MX2014014818A (pt)
WO (1) WO2013184586A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875052C (en) * 2012-06-05 2020-07-14 Olatec Industries Llc Method for treating skin inflammatory diseases
EP3110412B1 (en) * 2014-02-25 2018-10-31 Olatec Therapeutics LLC 4-benzylsulfonyl-2-butenenitrile
WO2018129231A1 (en) * 2017-01-06 2018-07-12 Olatec Therapeutics Llc Method for treating multiple sclerosis
CN110167538B (zh) * 2017-01-06 2022-11-29 欧拉泰克治疗有限责任公司 用于治疗心血管疾病的方法
CN111867678B (zh) * 2018-03-21 2023-04-28 欧拉泰克治疗有限责任公司 治疗黑色素瘤的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008532B1 (en) * 1978-08-22 1983-07-20 Sumitomo Chemical Company, Limited Synthesis of amines
DE3041155A1 (de) * 1980-10-31 1982-06-09 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen
US5175192A (en) 1984-03-19 1992-12-29 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
KR100294084B1 (ko) 1998-06-02 2001-09-22 성재갑 비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
WO2002076401A2 (en) * 2001-03-26 2002-10-03 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US7423064B2 (en) 2004-09-24 2008-09-09 Olatec Industries, Llc Composition for treating bacterial, viral, fungal diseases, inflammation and pain
MX2008011934A (es) 2006-03-20 2008-11-27 Olatec Ind Llc Composicion para el tratamiento de enfermedades bacterianas, virales micoticas, inflamacion y dolor.
US20100221337A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
US7851650B2 (en) 2009-03-18 2010-12-14 Olatec Industries Llc Compounds for treating inflammation and pain
BR112013014583A2 (pt) 2010-12-15 2016-09-20 Olatec Ind Llc composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila
CA2875052C (en) 2012-06-05 2020-07-14 Olatec Industries Llc Method for treating skin inflammatory diseases

Also Published As

Publication number Publication date
US20160256430A1 (en) 2016-09-08
US9592217B2 (en) 2017-03-14
MX2014014818A (es) 2015-02-12
BR112014030285B1 (pt) 2022-03-29
KR102112883B1 (ko) 2020-05-19
US9078869B2 (en) 2015-07-14
EP2854784A4 (en) 2016-01-20
US20160008314A1 (en) 2016-01-14
JP2015518886A (ja) 2015-07-06
WO2013184586A1 (en) 2013-12-12
AU2013271836A1 (en) 2015-01-22
CN104411303A (zh) 2015-03-11
AU2013271836B2 (en) 2018-03-01
CA2875052A1 (en) 2013-12-12
US20150080476A1 (en) 2015-03-19
US9278082B2 (en) 2016-03-08
KR20150018851A (ko) 2015-02-24
BR112014030285A8 (pt) 2021-06-22
CN104411303B (zh) 2017-09-05
EP2854784B1 (en) 2019-12-04
JP6185575B2 (ja) 2017-08-23
CA2875052C (en) 2020-07-14
EP2854784A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
BR112014030285A2 (pt) composição farmacêutica para tratar um distúrbio ou doença inflamatória da pele
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112014026424A2 (pt) composto, processo para produzir um composto de di-idrato, composto de benzotiofeno, método para prevenir e/ou tratar uma doença, e, composição farmacêutica
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112015008987A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
BR112016001954A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015024869A2 (pt) administração nasal
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
BR112014007257A2 (pt) composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
RU2013141845A (ru) Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112015025901A2 (pt) composto, composição, kit, e, métodos para corregular ras/raf/mek/erk e pi3k/akt/pten/mtor, para tratar uma condição e uma doença e para monitorar a eficácia de um composto
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015006790A2 (pt) composição de cetoprofeno tópico
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
JP2013542930A5 (pt)
BR112015024752A2 (pt) mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
BR112014030813A2 (pt) tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
BR112014013650A2 (pt) "formulações de pulverização oral e seus usos"
BR112015032529A2 (pt) composto de glicosaminoglicano e seu método de preparação, bem como sua aplicação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2013, OBSERVADAS AS CONDICOES LEGAIS.